The investigators will contact 64 patients with atopic dermatitis (AD) who participated in a long-term tacrolimus ointment trial in Helsinki 10 years ago, and ask them to participate in this follow-up study. The investigators will do the same tests as 10 years ago, i.e. bronchial hyperreactivity, skin prick tests, serum-IgE, Mantoux-test (2 TU), and questionnaires about asthma and allergic rhinitis symptoms. The investigators also collect data about their AD medication during the last 10 years. The investigators hypothesis is that when the skin condition improves in patients with AD the brochial hyperreactivity improves. The investigators also want to study whether different treatments play a role in the development or resolution of bronchial hyperreactivity.
We will by letters and telephone contact all patients (n=64) who fulfill the inclusion criteria for this study. The testing in the study (bronchial hyperreactivity, skin prick testing, serum IgE) is cross-sectional, but we retrospectively collect data from the last 10 years about the skin condition and medication for atopic diseases.
Study Type
OBSERVATIONAL
Enrollment
50
A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
One blood test to measure total serum IgE
Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
Skin- and Allergy Hospital, Department of Dermatology
Helsinki, Finland
Bronchial hyperreactivity
Time frame: 10 year follow-up
Skin prick tests
Time frame: 10 year follow-up
Serum-IgE
Time frame: 10-year follow-up
Mantoux-test
Time frame: 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.